Swati Palit Deb
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Mutations in tumor suppressor p53 that gain oncogenic functions (Onc-p53) are frequent in lungs and many other solid tumors often associated with chromosome aberrations. Why cells or tumors with Onc-p53 develop chromosomal aberrations and whether the abnormalities contribute to tumor growth remain elusive. Evidence in this communication demonstrate for the first time that replication stress induced by Onc-p53 triggers re-copying of DNA replication forks, which generates replication intermediates that cause persistent mitotic aberration and DNA segregation errors. Replication intermediates from re-copied replication forks induced by Onc-p53 activate ATM signaling, which stabilizes Onc-p53, reinforces its ability to upregulate replication factors for sustaining replication stress, thus generating a feedforward cycle accelerating tumor formation. In agreement with this observation our time lapse video microscopy show in real time that persistent mitotic aberration and DNA segregation errors induced by Onc-p53 confer selective growth advantage. Accordingly, human lung tumors with Onc-p53 show selection of cells with mitotic aberration during serial passages. Knock down of active replication forks reduces re-copied fork generation by Onc-p53 and specifically induces apoptotic death of lung cancer cells expressing Onc-p53 in xenograft lung tumors in cooperation with inhibitors of ATM activation, deselecting cells with Onc-p53 with mitotic errors. This communication reveals a novel mechanism which interconnects replication stress induced by Onc-p53 to its stabilization and ability to generate chromosomal aberration in lung cancer cells that both accelerate tumor growth and serve as a targetable therapeutic vulnerability. These findings will be extremely valuable for tumor-specific treatment of a high percentage of cancer patients with p53 mutation.
Year:
2026
Oncogenic p53 mutations (Onc-p53) are frequent in lung and many other solid tumors often associated with chromosome aberrations. Why cells with Onc-p53 develop chromosomal aberrations and whether the abnormalities contribute to tumor growth remain elusive. Evidence in this communication demonstrate for the first time that replication stress induced by Onc-p53 triggers re-copying of DNA replication forks, which generates replication intermediates that cause persistent mitotic aberration and DNA segregation errors. Replication intermediates from re-copied replication forks induced by Onc-p53 activate ATM signaling, which stabilizes Onc-p53, reinforces its ability to upregulate replication factors for sustaining replication stress, thus generating a feedforward cycle accelerating tumor formation. In agreement with this observation our time lapse video microscopy show in real time that persistent mitotic aberration and DNA segregation errors induced by Onc-p53 confer selective growth advantage. Accordingly, human lung tumors with Onc-p53 show selection of cells with mitotic aberration during serial passages. Knock down of active replication forks reduces re-copied fork generation by Onc-p53 and specifically induces apoptotic death of lung cancer cells expressing Onc-p53 in xenograft lung tumors synergistically in cooperation with inhibitors of ATM activation, deselecting cells with Onc-p53 with mitotic errors. This communication reveals a novel mechanism which interconnects replication stress induced by Onc-p53 to its stabilization and ability to generate chromosomal aberration in lung cancer cells that both accelerate tumor growth and serve as a targetable therapeutic vulnerability. These findings will be extremely valuable for tumor-specific treatment of a high percentage of cancer patients with p53 mutation.
Year:
2025
Non–small cell lung cancer (NSCLC) cells with oncogenic mutant p53 ( Onc-p53 ) alleles exhibit significantly higher levels of proteasome activity, indicating that Onc-p53 induces proteotoxic stress which may be leveraged as a therapeutic vulnerability. Proteasome inhibitors (PI) are most active in cells under proteotoxic stress, so we investigated whether PIs exhibit preferential cytotoxicity in Onc-p53 NSCLC cells. Indeed, bortezomib (BTZ) and other PIs exhibited IC 50 values 6- to 15-fold lower in Onc-p53 cells versus wild- type (WT) p53 cells. BTZ cytotoxic effects in Onc- p53 cells were abrogated by antioxidants such as N -acetyl-L-cysteine, indicating that oxidative stress is the critical driver of BTZ-dependent cytotoxic effects in Onc-p53 cells. Importantly, we observed oxidative stress–dependent transcriptional induction of the proapoptotic BH3-only protein NOXA, leading to cleavage of caspase-3, consistent with an apoptotic mechanism of cell death in Onc-p53 but not in WT p53 cells treated with BTZ. BTZ-generated oxidative stress was linked to nuclear translocation of NRF2 and transcriptional activation of ATF3, which in turn was required for NOXA induction. Validating the translational potential of BTZ in Onc-p53 NSCLC cells, BTZ and the BH3-mimetic navitoclax were synergistically cytotoxic in Onc-p53 but not in WT p53 cells in vitro , and BTZ effectively limited the growth of Onc-p53 NSCLC xenografts when combined with navitoclax and carboplatin (a standard-of-care chemotherapeutic in NSCLC) in vivo . Our data therefore support further investigation of the therapeutic utility of PIs combined with BH3-mimetics and chemotherapy in Onc-p53 human NSCLC as a novel therapeutic strategy. Significance: NSCLC is the leading cause of cancer death due, in part, to a lack of active therapies in advanced disease. We demonstrate that combination therapy with a proteasome inhibitor, BH3-mimetic, and chemotherapy is an active precision therapy in NSCLC cells and tumors expressing Onc-p53 alleles.
Year:
2025
BTZ induces ATF3/NOXA and caspase-dependent apoptosis. A, H1975 cells were pretreated (30 minutes) with vehicle or the pan-caspase inhibitor QVD-OPh (QVD; 1 µmol/L) and then treated with vehicle or BTZ (5 nmol/L) for 48 hours. Cell viability was determined by trypan blue exclusion assay. B, H1975 cells were treated as in A , and the percentage of apoptotic cells was determined by annexin V–propidium iodide staining followed by FACS analysis. C, Cell lysates from A were immunoblotted with the indicated antibodies. D, H1975 or H460 cells were treated with vehicle or 2 or 5 nmol/L of BTZ for 48 hours, and cell lysates were immunoblotted with the indicated antibodies. E, RNA from D was extracted and subjected to qRT-PCR with NOXA primers. F, H1975 cells stably expressing shC or shNOXA were treated with vehicle or BTZ (5 nmol/L) for 48 hours, and cell lysates were immunoblotted with the indicated antibodies. G, H1975 cells were treated with vehicle or 2 or 5 nmol/L of BTZ for 48 hours, and mRNA expression of ATF3 was analyzed by qRT-PCR. H, H1975 cells were treated with vehicle, NAC (1 mmol/L), BTZ (5 nmol/L), or BTZ + NAC for 48 hours, and cell lysates were immunoblotted with indicated antibodies. I, H1975 cells stably expressing control shRNA (shC) or ATF3 shRNA (shATF3) were treated with vehicle or BTZ (5 nmol/L) for 48 hours, and cell lysates were immunoblotted with the indicated antibodies. J, H1975 cells stably expressing shC or shATF3 were treated with vehicle or BTZ (5 nmol/L) for 48 hours, and the percentage of apoptotic cells was determined by annexin V–propidium iodide staining followed by FACS analysis. **, P P P > 0.05. Error bars indicate ± 1.0 SD. Cl. Casp 3, cleaved caspase-3.
Year:
2025
Navitoclax enhances BTZ-induced cytotoxicity. A and B, H1975 and H460 cells were treated with vehicle or the indicated concentrations of navitoclax with/without BTZ (2 nmol/L) for 96 hours. Cell viability was determined by WST-1 assay. C, H1975-Control or H1975-p53KO cells were treated with vehicle or the indicated concentrations of navitoclax with/without BTZ (5 nmol/L) for 96 hours. Cell viability was determined by WST-1 assay. D and E, NOD-SCID-II.2 receptor gamma null (NSG) mice were injected with 3.0 × 10 6 H1975 ( D ) or 1.0 × 10 6 H460 cells ( E ), and once tumors became palpable, mice were treated for 3 weeks with vehicle (control) or the combination of BTZ (1.0 mg/kg) 2×/week via intraperitoneal injection + navitoclax (NAV; 80 mg/kg) 3×/week via oral gavage + carboplatin (CBP; 25 mg/kg) once weekly via intraperitoneal injection. The period of treatment is indicated by the horizontal bar, and tumor volumes were measured twice weekly ( N = 6 mice/group). *, P P P P > 0.05. Error bars indicate ± 1.0 SD., except in D and E in which error bars indicate SEM.
Year:
2024
Onc-p53 regulates basal levels of 20S proteasome activity and is required for BTZ-induced cytotoxicity in NSCLC cells. A, 20S proteasome activity was determined in the indicated cell lines using a fluorometric proteosome activity assay and plotted as mean fluorescence units (MFU). All pairwise comparisons were made using the Student t test. B, (Left) Relative 20S proteasome activity in lysates of H1975-Control vs. H1975-p53KO cells. (Right) Cell lysates of H1975-Control and H1975-p53KO (p53KO) cell lines generated using CRISPR/Cas9 were immunoblotted with p53 and GAPDH antibodies. C, The indicated cells were treated with vehicle or increasing concentrations of BTZ (left) or CFZ (right) for 72 hours, and cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A paired t test was performed to analyze differences in viability among the cell lines. D, (Left) H1975-Control or H1975-p53KO cells expressing GFP or p53 R273H were treated with BTZ (5 nmol/L) for 48 hours, and cell viability was determined by trypan blue exclusion assay. (Right) Lysates of the indicated cell lines were immunoblotted with p53 and GAPDH antibodies. E, (Left) H460 or H460-p53KO ( 18 ) cells were treated with vehicle (−) or BTZ (5 nmol/L) for 72 hours, and cell viability was determined by WST-1 assay. (Right) Cell lysates of H460 and H460-p53KO cells were immunoblotted with p53 and GAPDH antibodies. F, (Left) H460-p53KO cells stably expressing GFP or p53 R273H were treated with increasing concentrations of BTZ for 72 hours, and cell viability was determined by WST-1 assay. (Right) Cell lysates of H460-p53KO cells stably expressing GFP or p53 R273H were immunoblotted with p53 and GAPDH antibodies. *, P P P P > 0.05. Error bars indicate ± 1.0 SD.
Year:
2024
The Onc-p53–NRF2–ATF3–NOXA pathway contributes to BTZ-induced apoptosis in Onc-p53 NSCLC cells. A, H1975 cells were treated with vehicle or BTZ (10 nmol/L) ± NAC (1 mmol/L) for 24 hours, and confocal immunofluorescence microscopy was performed using NRF2 antibody (red) and DAPI to highlight nuclei (blue). Representative individual and merged images (40× magnification) of NRF2 and DAPI stains are shown. B, H1975 cells were treated with vehicle, BTZ, or BTZ + NAC, followed by NRF2 and DAPI staining as in A and fluorescence microscopy. The percentage of cells with NRF2 localization exclusive to the nucleus was determined from 10 random fields (>10 cells/field counted) at 20× magnification. A pairwise comparison was made using the Student t test between the two groups. C, H1975 cells were treated with vehicle, NAC (1 mmol/L), BTZ (5 nmol/L), or BTZ + NAC for 48 hours, and cell lysates were immunoblotted with NRF2 and GAPDH antibodies. D, H1975 cells stably expressing control shRNA (shC) or NRF2 shRNA (shNRF2) were treated with vehicle or BTZ (5 nmol/L) for 48 hours, and cell lysates were immunoblotted with indicated antibodies. E, H1975 shC and shNRF2 cells were treated with vehicle or the indicated concentrations of BTZ for 72 hours, and cell viability was determined by WST-1 assay. F, H1975-Control or H1975-p53KO cells were treated with vehicle (−) or BTZ (5 nmol/L) for 48 hours, followed by immunoblotting of cell lysates with indicated antibodies. **, P P
Year:
2024
Onc-p53 NSCLC cells exhibit basal and PI-induced oxidative stress. A, Average oxidized (GSSG) vs. reduced (GSH) levels of GSH obtained from metabolomic profiles (DepMap) of NSCLC cell lines that either express Onc-p53 protein (Onc-p53) or lack p53 protein expression due to homozygous deletion/frameshift/premature termination mutations (loss of function; LOF). Data were analyzed using the unpaired t test. B, GSH concentration was determined in lysates of the indicated cell lines. C, Relative GSH concentrations were determined in lysates of H1975-Control vs. H1975-p53KO cells. D, Levels of ROS were determined in the indicated cell lines using a fluorescent ROS detection assay and plotted as mean fluorescence units (MFU). E, H460 or H1975 cells were treated with vehicle, BTZ (5 nmol/L), NAC (1 mmol/L), or BTZ + NAC for 24 hours. Relative ROS levels normalized to vehicle treatment for each cell line were determined by staining with DCFH-DA followed by flow cytometry. F, H1975 cells were treated as per E for 48 hours, and cell viability was assessed by trypan blue exclusion. All pairwise comparisons were made using the Student t test. *, P P P
Year:
2024
Collaborators (7)
Jorge Nieva
Professor of Clinical Medicine
University of Southern California
Steven R. Grossman
University of Southern California
Hisashi Harada
Virginia Commonwealth University
Eziafa Oduah
Assistant Professor
Duke University
sumitra deb
Virginia Commonwealth University
Senthil K. Radhakrishnan
Virginia Commonwealth University
Jennifer Koblinski
Assistant professor, Director Cancer Mouse Models Core
Virginia Commonwealth University
Make your next move.
Prepare your application
Review drafts before you send them.